Stock XOMA.O XOMA ROYALTY CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Ratings XOMA Royalty Corporation Nasdaq

Equities

XOMA.O

US98419J4040

Market Closed - Nasdaq
Other stock markets
 02:00:01 17/07/2024 am IST 		5-day change 1st Jan Change
24.92 USD -0.91% Intraday chart for XOMA Royalty Corporation -0.48% -0.80%
10/07 XOMA Corporation will Change its Name to XOMA Royalty Corporation CI
09/07 Xoma Changes Name to Xoma Royalty MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Analyst opinion has improved significantly over the past four months.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
XOMA ROYALTY CORPORATION Stock XOMA Royalty Corporation
-0.80% 31Cr -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+20.17% 13TCr
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+24.67% 12TCr
B+
ARGENX SE Stock argenx SE
+25.44% 2.77TCr
B
BIONTECH SE Stock BioNTech SE
-17.74% 2.03TCr
B+
GENMAB A/S Stock Genmab A/S
-15.17% 1.68TCr
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-15.21% 1.56TCr
B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+11.91% 1.48TCr
C+
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-47.10% 1.46TCr
A-
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+54.50% 1.44TCr
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. XOMA Stock
  4. XOMA.O Stock
  5. Ratings XOMA Royalty Corporation